Metraipolis › archive › dc_ffbaa539fa3b

Rituximab for refractory minimal change disease: Long-term outcomes in the remission maintenance phase — Europe PMC PMID:41465977

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41465977
DOI
10.1097/md.0000000000046798
License (as archived)
solo-consultazione
Archived
2026-11-08T02:34:32.065Z
SHA-256 of the archived text
3ddfd815f6d6c6db9c1b86565f89e819b94f67ad994d5cbea69b0777878a49c2
Stable URL of this page
https://metraipolis.com/documento/dc_ffbaa539fa3b

How to cite

Rituximab for refractory minimal change disease: Long-term outcomes in the remission maintenance phase — Europe PMC PMID:41465977 — Europe PMC (en), https://europepmc.org/article/MED/41465977 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ffbaa539fa3b (Metraipolis archive dc_ffbaa539fa3b, sha256 3ddfd815f6d6c6db9c1b86565f89e819b94f67ad994d5cbea69b0777878a49c2)
BibTeX
@misc{dcffbaa539fa3b,
  title = {Rituximab for refractory minimal change disease: Long-term outcomes in the remission maintenance phase — Europe PMC PMID:41465977},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41465977},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ffbaa539fa3b; sha256 3ddfd815f6d6c6db9c1b86565f89e819b94f67ad994d5cbea69b0777878a49c2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41465977. Agents can read the archived copy with the MCP tool read_document.